Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines

Digestion

Volumn 74, Issue 1, 2006, Pages 19-27

  Gu, Jinyu ^a,b   Yamamoto, Hirofumi ^a,d   Lu, Xueying ^a   Ngan, Chew Yee ^a   Tsujino, Tadashi ^a   Konishi, Ken ^a   Takemasa, Ichiro ^a   Ikeda, Masataka ^a   Nagata, Hiroshi ^c   Hashimoto, Shusuke ^c   Matsuzaki, Takeshi ^c   Sekimoto, Mitsugu ^a   Takagi, Akimitsu ^c   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Gastric cancer; Mitotic catastrophe; Oxaliplatin; Paclitaxel; Survivin

Indexed keywords

OXALIPLATIN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICROTUBULE-ASSOCIATED PROTEINS; MITOSIS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; STOMACH NEOPLASMS;

EID: 33751545547     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095826     Document Type: Article

References (23)

1. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;54-59.
2. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaine MA, Itzhaki M, Marty M, Extra JM: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 1999;10:1125-1128.
3. Delaloge S, Laadem A, Taamma A, Chouaki N, Cvitkovic E, Pautier P, Misset JL, Lhomme C: Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol 2000;23:569-574.
4. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE: A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004;15:915-920.
5. Van Cutsem E: The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9(suppl 2):9-15.
6. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002;13:497-503.
7. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37-41.
8. Rougier P, Lepere C: Metastatic colorectal cancer: first- and second-line treatment in 2005. Semin Oncol 2005;32(6 suppl 8):15-20.
9. Zaniboni A, Meriggi F: The emerging role of oxaliplatin in the treatment of gastric cancer. J Chemother 2005;17:656-662.
10. Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, Harada M, Nakano S: In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 2005;55:595-601.
11. Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P: Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 2002;64:1215-1226.
12. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M: Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005;35:453-463.
13. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis 1. Gastroenterology 2003;125:556-571.
14. Mielke S, Sparreboom A, Mross K: Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42:24-30.
15. Cersosimo RJ: Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-135.
16. Blagosklonny MV, Robey R, Sheikh MS, Fojo T: Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther 2002;1:113-117.
17. Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M: A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 2003;57:412-415.
18. Xiao Z, Xue J, Semizarov D, Sowin TJ, Rosenberg SH, Zhang H: Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int J Cancer 2005;115:528-538.
19. Toiyama Y, Tanaka K, Konishi N, Mohri Y, Tonouchi H, Miki C, Kusunoki M: Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45. Cancer Chemother Pharmacol 2006;57:368-375.
20. Jonathan EC, Bernhard EJ, McKenna WG.: How does radiation kill cells? Curr Opin Chem Biol 1999;3:77-83.
21. Ling X, Bernacki RJ, Brattain MG, Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 2004;279:15196-15203.
22. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
23. Zaffaroni N, Pennati M, Daidone MG: Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360-372.